Companies: 10,795·Total market cap: $144.5T
BioLineRx Ltd.

BioLineRx Ltd.

BLRXNASDAQHealthcare● Active
$3.21
$-0.02(-0.62%)
Market Cap$13967856
P/E Ratio
52W High$6.59
52W Low$2.15
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

BioLineRx Ltd. (BLRX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001498403 · BLRX · NASDAQ · as of Jun 8, 2026

Filing snapshot

604
Total Filings
6-K
Latest Form
2026-05-27
Most Recent
2011
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001498403 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-03-23
Fiscal Year End
Mar 23, 2026
Accession No.
0001178913-26-001581
Primary Document
zk2634707.htm
Source: data.sec.gov · CIK 0001498403 · Accession 0001178913-26-001581

Latest Key Filings

6-KQuarterly Report
6-K
2026-05-27
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-27
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-22
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-19
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-28
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-04-10
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-31
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-31
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-31
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-31
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-03-30
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-03-30
View
20-F/A20-F/A
20F/A
2026-03-27
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-03-27
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-03-26
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-03-23
View
Showing 1–15 of 604 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001498403  |  Exchange: NASDAQ · Healthcare

BioLineRx Ltd. (NASDAQ: BLRX) has submitted 604 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2011. As a Healthcare sector company with CIK 0001498403, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is BioLineRx Ltd.'s most comprehensive regulatory disclosure. The most recent BioLineRx Ltd. 10-K was filed on 2026-03-23 for fiscal year ending 2026. Historical BLRX 10-K annual reports are available from 2010 through 2026.

Investors researching BioLineRx Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

BLRX SEC Filings · 8 questions

BioLineRx Ltd. (BLRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 604 filings and access original documents at no cost. BioLineRx Ltd.'s CIK is 0001498403.

BLRX SEC filingsBioLineRx Ltd. SEC documentsfind BLRX 10-K